In studies of cerebral glucose metabolism utilising positron emission tomography (PET) with '8F-fluoro-2-deoxy-D-glucose, patients with the clinical picture of progressive supranuclear palsy (PSP) have shown predominantly frontal glucose hypometabolism. This is presumed to represent deafferentation of cerebral cortical from subcortical structures. In these studies, however, the diagnosis of PSP has not been verified by pathological examination. Necropsy examinations were performed in three patients with the clinical features of PSP in whom PET had demonstrated predominantly frontal hypometabolism. In two of these patients the diagnosis of PSP was confirmed pathologically, and no morphological abnormalities were found in the cerebral cortex. The third patient had extensive cortical and subcortical neuronal loss and gliosis without neurofibrillary tangles, consistent with the diagnosis of progressive subcortical gliosis (PSG). Even in retrospect no unique clinical neurological abnormality or finding on laboratory investigation could be identified that distinguished this latter patient from those with pathologically confirmed PSP. We conclude that PSG and PSP may be indistinguishable during life, and necropsy confirmation is needed for definite diagnosis.
At present the clinical diagnosis of progressive supranuclear palsy (PSP) depends upon the recognition of typical clinical signs. Diagnosis is difficult since the characteristic signs of the disease can develop sequentially and misdiagnoses are frequent. Particularly early in the illness, PSP is often mistaken for Parkinson's disease (PD) . Fortunately, recent studies have indicated that PSP is typically associated with predominantly frontal glucose hypometabolism measured by positron emission tomography (PET) studies with '8F-fluoro-2-deoxy-D-glucose (FDG).' 2 Since the regional distribution of glucose metabolism in patients with PD is normal34 or, when dementia is also present, there is predominantly posterior temporoparietal hypometabolism,4 PET is a helpful adjunct in distinguishing PSP patients from those with PD.5 Occasionally PSP is mistaken for Alzheimer's disease. 6 In this case PET may help since predominantly posterior temporoparietal hypometabolism is typically seen in Alzheimer's disease. While functional brain imaging may sometimes assist in the differential diagnosis of PSP, significant diagnostic obstacles still exist.
Many neurological disorders cause clinical signs that are similar to those seen in PSP. A downgaze supranuclear gaze palsy, the clinical hallmark of PSP, can occur in disorders as diverse asWhipple's disease, multiple sclerosis, syphilis, brucellosis and Fisher's syndrome.7 Downgaze supranuclear ophthalmoplegia accompanied by dementia or signs of extrapyramidal disease has been reported in several disorders, such as autosomal dominant olivopontocerebellar atrophy,8 diffuse Lewy body disease,9 advanced amyotrophic lateral sclerosis, Huntington's disease, Jakob-Creutzfeldt disease,'0 Niemann-Pick disease type C," and progressive subcortical gliosis (PSG).'2 Thus the pitfalls of clinical diagnosis of PSP are substantial. In addition, in one series, 19 of 58 patients with clinical features of PSP had CT or MRI evidence of a multi-infarct state (which may or may not have been responsible for the PSP symptoms). One of these patients at necropsy had multiple small infarcts due to cerebral amyloid angiopathy without pathological features typically found in PSP. ' 3 However, this article mentions only the presence of a vertical supranuclear gaze palsy, without specifying whether downgaze was involved. Another paper reporting reversible supranuclear palsy (including downgaze palsy) due to Parkinson's disease is difficult to interpret in the face of a history of concurrent infection in each case, limited information about the patients' clinical course and the absence of pathological data.'4 Multiple system atrophy (MSA) may also exhibit supranuclear gaze palsy, but it has been proposed that a predominant downgaze paresis should constitute an exclusion criterion for the clinical diagnosis of MSA. " We were able to examine the clinical utility of PET in the differential diagnosis of PSP by reviewing our findings in three patients with the clinical diagnosis of PSP who had participated in a study of FDG-PET2 and subsequently died and had postmortem examinations. Although all of these patients had the typical clinical features of PSP, one was subsequently found at necropsy not to have PSP, but rather a multisystem degeneration with a constellation of features best described as PSG.'2 16 17 This disorder is pathologically distinct from PSP in that there is a complete absence of subcortical neurofibrillary tangles.
Subjects and methods In a previous study2 14 patients with typical clinical features of PSP and 21 normal controls of similar age were scanned with FDG-PET and received a standard battery of neuropsychological tests. The selection criteria for these subjects, scanning conditions and technique, are described in our previous report.2 For this study we have used the data obtained in our previous study and calculated several additional measures for comparison of individual patients. The most superior transverse slice through the top of the centrum semiovale was further analysed, since cerebral cortical hypometabolism was found to be most affected at this level in our earlier study. Frontal cortex metabolism was determined by computing the mean value of 4 anterior sectors in this slice (regions 2 and 3 in each hemisphere as illustrated in figure 1 of reference 2), and relative frontal metabolism was the ratio of this value to mean overall cerebral cortical metabolism. An anterior to posterior ratio was also calculated (regions 2 and 3/regions 6 and 7 from figure 1 in reference 2), since this ratio has been found useful in distinguishing Alzheimer's disease and Parkinson's disease with dementia from normal subjects and from patients with PSP. 18 Five of the 14 patients we studied have subsequently died. In two necropsy could not be obtained. The other three have been studied postmortem with a standard protocol that includes gross and microscopic examination, including haematoxylin-eosin, phosphotungstic acid-haematoxylin, luxol fast blue-cresyl violet-eosin, and pyridine silver carbonate stains. In table 2 we have classified the 11 patients not examined at postmortem as having "probable" PSP.
Results
The clinical features of the three necropsy cases are summarised in table 1. Each of these individuals was observed over several years. At the time of their PET study all were given the clinical diagnosis of PSP, and this diagnosis remained unchanged throughout their illnesses. As we have previously reported,'9 neuropsychological performance was significantly impaired in subjects with probable PSP compared with controls, and similar impairments were observed in all three patients at necropsy. This level of ability represented a decline from premorbid abilities ascertained by history in all three, but the patient with PSG had somewhat more severe impairments of memory relative to his intellectual abilities than the others at the time of his scan (table 2).
All of the patients had predominantly frontal hypometabolism in the cerebral cortex compared with normal controls of similar age (table 2). The three pathologically examined patients had average glucose metabolic rates in the cerebral cortex below the mean of normals and within the range of those observed in the probable PSP group. Metabolic rates in the frontal cortex relative to the rest of the cerebral cortex, and relative to posterior cortical regions were more than 2 standard deviations below that observed in the normal subjects (table 2) . This was even more marked in the PSG patient than in the definite PSP patients. In these patients, even though only a few individual regions had metabolic rates that were more than 2 standard deviations from normal, almost all values were closer to those observed in the PSP subjects than in normals. All demonstrated a similar anterior to posterior gradient for metabolism that was like that seen in the probable PSP group (figure 1).
Despite these metabolic similarities, the patient with PSG had substantial neuronal loss and astrocytic gliosis in the frontal cortex, whereas no abnormalities were found in the cerebral cortex of patients with PSP (table 3) . Metabolism of the caudate nucleus, putamen, pons, and thalamus in all three patients was below the mean of the normal controls and similar to that seen in the patients with ,probable PSP ( 
Case 3 PSP
.nuclear palsy, N = hied astrocytes), T throughout the corticospinal tracts in the internal capsule, the crus cerebri, pons and the pyramids of the medulla ( figure 3) tion of her right leg when walking. She also had difficulty chewing and swallowing, choking frequently. Her symptoms were not relieved by treatment with levodopa/carbidopa, bromocriptine, or lioresal.
In August 1986, when a PET study was performed, all ofher symptoms had progressed so that she spoke infrequently, had increasing difficulty swallowing, walked poorly, and often fell. On examination she was fully oriented and had a good fund of knowledge, but was poor at calculation and abstraction. She needed assistance with the upper arms when rising from a chair. Her posture was stooped and she walked slowly with freezing and festination. Her balance was poor so that she would fall if not caught. Visual acuity, pupillary reflexes and visual fields were normal. There was an exophoria of five prism diopters and large amplitude square wave jerks during both near and distant fixation. Voluntary eye movements were limited to 80% of normal with horizontal gaze, 5% of normal in upgaze and 60% of normal in downgaze. Saccades were slow and hypometric, pursuit movements were saccadic, and optokinetic nystagmus was deficient with horizontally moving targets and absent with vertically moving targets. Oculocephalic reflexes and Bell's phenomenon were intact. The face showed poor expressiveness, and speech was moderately dysarthric, with spastic and hypokinetic components. The gag reflex was hyperactive, and glabellar, palmomental, and snout reflexes were present. There was marked rigidity of the neck and the right upper extremity, less rigidity in the left upper extremity, and tremor at rest in both upper extremities, worse in the left than the right. The reflexes were 3+ throughout and the plantar responses were flexor. On neuropsychological testing impaired function was noted on all cognitive tasks except for the retention of newly learned materials, which was relatively maintained ( extension, but rigidity was present in the extremities only upon activation. Horizontal gaze was limited to 50% of normal, upgaze to 10% of normal and downgaze was absent. Movements were uncoordinated and slow, and her writing had become illegible. In July 1988 she was admitted to hospital for a gastrostomy because of progressive inability to swallow. She died in a nursing home at the age 70.
Pathology The brain weighed 1340 grams and was normal on gross examination. On microscopic examination the findings were similar to case 2. The frontal, temporal and parietal cortex were normal and no neurofibrillary tangles or neuritic plaques were seen.
There was neuronal loss with moderate astrogliosis in the globus pallidus, dorsal part of the amygdala, anterior thalamus, and dentate nucleus. Moderate neuronal loss and gliosis was noted in the inferior olivary nucleus. The substantia nigra showed moderate neuronal loss and gliosis. Neurofibrillary tangles were demonstrated in the globus pallidus and periaqueductal grey. Discussion PSP is characterised pathologically by localised neuronal loss, gliosis, and distinctive neurofibrillary tangles conspicuously affecting the globus pallidus, subthalamic nucleus, red nucleus, substantia nigra, dentate nucleus, tectum, and periaqueductal grey matter. The caudate nucleus and putamen are less affected and the cerebral cortex is generally spared. 20 21 PSG is an entity with neuropathological changes within extrapyramidal, pyramidal and cerebellar systems.'2 16 17 The characteristic features are widespread neuronal loss and gliosis, but without distinctive morphological changes such as Lewy bodies or neurofibrillary tangles. These changes are variable in distribution from one patient to another, but usually involve the basal ganglia, inferior olives, pontine nuclei, cerebellum, Purkinje cells, and frequency the cerebral cortex.
"
The clinical symptoms and signs of PSP and PSG can be similar. 12 PSP causes supranuclear palsy of gaze, axial dystonia, pseudobulbar palsy with dysarthria and dysphagia, bradykinesia, rigidity, and a progressive dementia.202' PSG causes a variety of symptoms and its clinical recognition is difficult since it can present with signs of disease affecting extrapyramidal, pyramidal, and cerebellar pathways, as well as dementia. Although it would be reassuring if a particular clinical feature could be relied upon to distinguish these two disorders, this is not possible because multiple subcortical structures are involved in both. Each of the symptoms exhibited in our patients has been reported previously in individuals with pathologically verified PSP or PSG. Abnormal eye movements, including voluntary upgaze and downgaze paresis, were seen in all of our subjects. While the loss of upgaze more than downgaze is not common in PSP, it cannot be considered a reliable sign of PSG, since it was also seen in one of our patients with PSP. Likewise, resting tremor cannot be used to identify these disorders, since it has been observed in patients with PSG,12 it was seen in one of our patients with PSP, and it is a typical feature of Parkinson's disease. The Babinski signs seen in our patient with PSG appeared only late in his illness and probably reflect the neuronal loss and gliosis observed in the cerebral cortex and degeneration of the corticospinal tracts. These signs of corticospinal tract disease cannot be used to distinguish PSG from PSP, since these signs, including Babinski reflexes, have also been observed in patients with pathologically confirmed PSP.21
Neuropsychological testing does not distinguish PSG from PSP subjects, but our results leave open the possibility that there may be some differences in the cognitive impairments in these two conditions. Memory and recall on tasks of new learning were substantially more impaired in our PSG patient than in either of the PSP patients. For example, subject 1 had a memory quotient 17 points lower than subject 2 even though their full scale intelligence scores were identical. As we have previously reported in patients with dementia,'9 the degree of relative frontal hypometabolism in these patients paralleled the severity of their impairment of verbal fluency, a disturbance that is likely mediated by the frontal lobe. Structural brain imaging also does not differentiate PSG from PSP. In our patient with PSG, cerebral atrophy appeared grossly to be more pronounced than in the two patients with PSP, but this is a non-specific finding. Both CT and MRI can show cerebral and brainstem atrophy in patients with PSP,22 24 but this is difficult to quantitate, and was not apparent in our cases. Decreased T2 relaxation times can be seen in the putamen, globus pallidus, and superior colliculi with high field MRI, but this finding does not appear to differentiate PSP from other neurodegenerative disorders. 24 FDG-PET may have utility in differentiating PSP and PSG from other conditions. Our findings confirm our previous observation that PSP causes predominantly frontal hypometabolism in the cerebral cortex and hypometabolism in several subcortical structures with relative sparing of the cerebellum2 and provide preliminary evidence that PSG can cause a similar abnormalities. This pattern is unlike the typical findings in patients with Parkinson's disease, Parkinson's disease with dementia, Alzheimer's disease, familial and sporadic olivopontocerebellar atrophy or normal control subjects.2 25 Unfortunately, FDG-PET cannot reliably distinguish between PSP and PSG, as our patients illustrate, and clinically diagnosed striato-nigral degeneration also exhibits similar abnormalities. 26 It is easier to demonstrate differences in metabolism between diagnostic groups, than to make diagnostic decisions in an individual. The similarities in the pattern of metabolism of Cases 1-3 to the PSP subjects lead the observer to classify them with the PSP cases, even though in all 3 only relative frontal hypometabolism is statistically different from normal controls. Although PSP patients as a group clearly have subcortical hypometabolism, in a particular individual this may not be apparent. Subcortical metabolic rates in the patients at necropsy were not more than 2 standard deviations below the mean of normals, but it can not be concluded that subcortical regions were unaffected. Subcortical metabolic rates in the necropsy patients were below the mean value of normal controls, and pathological abnormalities were later documented. Likewise, it is dangerous to draw conclusions about a diagnostic group from a single case. Although the pons was less hypometabolic in the patient with PSG than in PSP subjects, it is doubtful whether this is of any significance. PET will more dependably distinguish various multiple system degenerations in individual patients when FDG studies can be augmented by studies using more selective and specific ligands.
While the metabolic patterns of PSP and PSG may be similar, their origins in these two disorders appear to differ. Morphological changes in the cerebral cortex have been described occasionally in patients with PSP, 27 and therefore the cause of the frontal hypometabolism seen in this condition with FDG-PET has been unresolved. However, since no pathological abnormalities were seen in the cerebral cortex of our patients with definite PSP, cerebral hypometabolism in these patients seems to be due to deafferentation alone, as was suggested previously.' 2 Conversely, in our patient with PSG it is likely that both deafferentation and intrinsic pathology account for the metabolic abnormalities in the cerebral cortex. Neuronal loss and gliosis in the cerebral cortex was not uniformly distributed and was most marked in the frontal cortex corresponding to the areas of greatest metabolic deficit. In both PSP and PSG, the subcortical hypometabolism appears to be a combination of intrinsic pathology and disconnection since no strict correlation between metabolism and pathology could be obtained. 
